Fig. 7.
The OsCESA9D387N mutation does not affect secondary cell wall CSC trafficking. a Western blotting analysis of OsCESA4, OsCESA7 and OsCESA9 with their polyclonal antibodies in microsomal pellet between WT and sdbc1 plants. Ponceau S, loading control; TM, total membrane. b and c Western blotting analysis of OsCESA4, OsCESA7 and OsCESA9 in DEX (endomembrane) and PEG (plasma membrane) fractioned membrane proteins extracted from WT and sdbc1 plants. DEX, the endomembrane fraction; PEG, the plasma membrane fraction; Anti-BiP2 and Anti-PIP1s antibodies are used to label the marker protein in the endomembrane and plasma membrane, respectively. Western blotting analysis has been repeated for at least three times